主要文件

查看所有文档

Y0001598

度他雄胺

Name: 度他雄胺
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

别名:

(5α,17β)-N-[2,5-双(三氟甲基)苯基] -3-氧代-4-氮杂杂芳-1-烯-17-羧酰胺

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₂₇H₃₀F₆N₂O₂

化学文摘社编号:

164656-23-9

分子量:

528.53

NACRES:

NA.24

PubChem Substance ID:

329831503

UNSPSC Code:

41116107

MDL number:

MFCD00937869

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

pharmaceutical primary standard

API family

dutasteride

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

O=C1C=C[C@@]2(C)[C@](CC[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@@H]4C(NC5=CC(C(F)(F)F)=CC=C5C(F)(F)F)=O)([H])N1

InChI

1S/C27H30F6N2O2/c1-24-11-9-17-15(4-8-21-25(17,2)12-10-22(36)35-21)16(24)6-7-19(24)23(37)34-20-13-14(26(28,29)30)3-5-18(20)27(31,32)33/h3,5,10,12-13,15-17,19,21H,4,6-9,11H2,1-2H3,(H,34,37)(H,35,36)/t15-,16-,17-,19+,21+,24-,25+/m0/s1

InChI key

JWJOTENAMICLJG-QWBYCMEYSA-N

Gene Information

human ... SRD5A1(6715), SRD5A2(6716), SRD5A3(79644)

说明

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Dutasteride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Still not finding the right product?

Explore all of our products under 度他雄胺

pictograms

GHS08

signalword

Danger

hcodes

H351,H360FD

pcodes

P201 - P308 + P313

Hazard Classifications

Carc. 2 - Repr. 1B

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

涉药品监管产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Effect of dutasteride in men receiving intermittent androgen ablation therapy: The AVIAS trial.

Laurence Klotz et al.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 8(11-12), E789-E794 (2014-12-09)

We studied the effect of dutasteride on the length of the off-treatment period in prostate cancer patients on intermittent androgen deprivation (IAD) therapy. We conducted a randomized, placebo-controlled Phase II trial in men with localized prostate cancer and a rising

Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis.

Elahe A Mostaghel et al.

PloS one, 9(10), e111545-e111545 (2014-10-31)

Factors influencing differential responses of prostate tumors to androgen receptor (AR) axis-directed therapeutics are poorly understood, and predictors of treatment efficacy are needed. We hypothesized that the efficacy of inhibiting DHT ligand synthesis would associate with intra-tumoral androgen ratios indicative

Impact of dutasteride on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): a pooled analysis of three phase III studies.

Matthias Oelke et al.

World journal of urology, 32(5), 1141-1147 (2014-06-07)

To assess the impact of dutasteride compared with placebo on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia, using pooled data from dutasteride phase III studies. Nocturia was assessed using Question 7 of the International

查看所有相关文献

全球贸易项目编号

货号	GTIN
Y0001598	04061837584985